Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics-Reference-Cited by-同舟云学术

Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics

Published:2006 Issue: Volume: Page:213-268
ISSN:0065-230X
Container-title:Advances in Cancer Research
language:
Short-container-title:

Author:

Sarker Debashis,Workman Paul

Publisher

Elsevier

Reference212 articles.

1. Use of positron emission tomography in anticancer drug development;Aboagye;Invest. New Drugs,2003

2. Intracellular signal transduction pathway proteins as targets for cancer therapy;Adjei;J. Clin. Oncol.,2005

3. Ethics of phase 1 oncology studies: Reexamining the arguments and data;Agrawal;JAMA,2003

4. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition;Albanell;J. Clin. Oncol.,2002

5. Comparison of PET, CT, and dual‐modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors;Antoch;J. Nucl. Med.,2004

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From lab to clinic: The discovery and optimization journey of PI3K inhibitors;European Journal of Medicinal Chemistry;2024-11

2. Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine;Journal of Personalized Medicine;2024-07-03

3. Proteomics and Its Applications in Cancers 2.0;International Journal of Molecular Sciences;2024-04-18

4. Clinical Pharmacology in Oncology;Tata Memorial Centre Textbook of Oncology;2024

5. Molecular Pathology: Applications in Nonclinical Drug Development;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024